Price
Target price
-
-
-
-
-
?7.88
WKN: A1W77U / Symbol: KPTI / Name: Karyopharm / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Karyopharm Therapeutics Inc. Stock
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Karyopharm Therapeutics Inc..
Based on the current price of 0.54 € the target price of 7 € shows a potential of 1193.42% for Karyopharm Therapeutics Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Karyopharm Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.
Pros and Cons of Karyopharm Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karyopharm Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | - | - | - | - | - | - | - |
| Krystal Biotech | -0.270% | 9.516% | 0.749% | -25.029% | -16.064% | 58.696% | - |
| Ardelyx Inc. | 0.100% | 9.942% | 27.965% | -6.831% | -1.108% | 450.634% | 3.325% |
| Evolus Inc | 0.940% | 0.952% | -33.750% | -55.833% | -49.524% | -43.011% | 70.254% |
Comments
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Robert W. Baird from $42.00 to $25.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Royal Bank of Canada from $34.00 to $33.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
News
Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q4 2024 Earnings CallFeb 19, 2025, 8:00 a.m. ET
Operator
Source Fool.com
